Outcomes among patients with chronic obstructive pulmonary disease after recovery from COVID-19 infection of different severity
Scientific Reports,
Год журнала:
2024,
Номер
14(1)
Опубликована: Июнь 16, 2024
Abstract
While
studies
have
suggested
increased
risks
of
severe
COVID-19
infection
in
chronic
obstructive
pulmonary
disease
(COPD),
the
persistent
and
delayed
consequences
on
patients
with
COPD
upon
recovery
remain
unknown.
A
prospective
clinical
study
was
conducted
Hong
Kong
to
investigate
outcomes
who
had
different
severity
(mild-moderate
COVID-19),
compared
those
did
not.
Chinese
≥
40
years
old
were
recruited
from
March
September
2021.
They
prospectively
followed
up
for
24.9
±
5.0
months
until
31st
August
2023.
The
primary
outcome
deterioration
control
defined
as
change
mMRC
dyspnea
scale.
secondary
included
exacerbation
frequency
non-COVID-19
respiratory
mortality
(including
death
or
bacterial
pneumonia).
328
analysis.
Patients
mild-moderate
statistically
significant
worsening
dyspnoea
scale
by
increase
1
score
baseline
follow-up
adjusted
odds
ratios
4.44
(95%
CI
=
1.95–10.15,
p
<
0.001)
6.77
2.08–22.00,
respectively.
significantly
4.73
1.55–14.41,
0.006)
pneumonia
hazard
ratio
11.25
2.98–42.45,
0.001).
After
COVID-19,
dyspnea,
(COPD
pneumonia)
observed
among
COVID-19.
Mild
moderate
also
associated
symptomatic
deterioration.
Язык: Английский
DElaying disease Progression In COPD with early escalation to Triple therapy – A Modelling Study (DEPICT-2)
ERJ Open Research,
Год журнала:
2024,
Номер
unknown, С. 00438 - 2024
Опубликована: Авг. 22, 2024
In
patients
with
COPD,
dual
bronchodilator
(long-acting
muscarinic
antagonist
(LAMA)/long-acting
β2-agonist
(LABA))
and
triple
therapy
(inhaled
corticosteroid/LAMA/LABA)
reduce
the
risk
of
exacerbations
lung
function
decline
in
short-mid-term,
but
their
long-term
impact
is
unknown.
This
modelling
study
explores
these
therapies
on
decline,
quality
life
(QoL)
all-cause
mortality.
approach
used
a
longitudinal
nonparametric
superposition
model
using
published
data
regarding
exacerbations,
QoL
(assessed
by
St
George's
Respiratory
Questionnaire
(SGRQ))
The
simulated
disease
progression
from
40
to
75
years
age
assessed
initiating
at
45
("LAMA/LABA
only"
group)
escalation
50
("Escalation
triple"
forced
expiratory
volume
1
s
(FEV1)
Model
simulation
predicted
that
age,
"LAMA/LABA
preserves
159.1
mL
FEV1
versus
no
treatment,
while
"Escalation
an
additional
376.5
217.3
pharmacotherapy
only",
respectively.
SGRQ
score
reduces
(-3.2)
which
further
-7.5
triple".
mortality
5.4%
shows
decrease
12.0%.
Early
initiation
could
slow
preserving
improving
survival
COPD.
Язык: Английский
Increased Pneumonia Risk Associated with Concomitant Use of Inhaled Corticosteroids and Benzodiazepines: A Pharmacovigilance Analysis
Lung,
Год журнала:
2024,
Номер
202(5), С. 673 - 681
Опубликована: Авг. 27, 2024
Язык: Английский
Εosinophilic Chronic Obstructive Pulmonary Disease. What Do We Know So Far?
Pulmonary Therapy,
Год журнала:
2024,
Номер
11(1), С. 7 - 24
Опубликована: Дек. 11, 2024
The
latest
advances
in
asthma
treatment
have
highlighted
the
significance
of
eosinophilia
and
possible
role
some
pro-eosinophilic
mediators,
like
interleukins
(IL)
IL-5,
IL-4/IL-13,
IL-33
disease's
pathogenesis.
Considering
that
a
subgroup
patients
with
chronic
obstructive
pulmonary
disease
(COPD)
may
blood
akin
to
seen
asthma,
numerous
studies
last
decade
suggested
eosinophilic
COPD
is
separate
entity.
While
exact
eosinophils
pathophysiology
remains
unclear,
seems
increase
effectiveness
corticosteroid
therapy.
Currently,
monoclonal
antibodies
targeting
(IL-5,
IL-4,
IL-13,
IL-33)
or
their
receptors
are
being
investigated
belonging
T2-high
endotype.
This
review
focuses
on
mechanisms
COPD,
effects
outcome,
examines
most
recent
data
use
peripheral
treating
COPD.
Finally,
we
emphasize
current
implication
context
airway
inflammation.
Язык: Английский